Cargando…
Focus on biosimilar etanercept – bioequivalence and interchangeability
BACKGROUND: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the management of rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis due to the considerably lower cost of these products and the consequent saving...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121755/ https://www.ncbi.nlm.nih.gov/pubmed/30214149 http://dx.doi.org/10.2147/BTT.S126854 |